1. |
何礼贤.值得研究和借鉴的短程抗菌治疗策略.中国抗感染化疗杂志,2005,5:318-319.
|
2. |
Mandell LA.Update on community-acquired pneumonia.New pathogens and new concepts in treatment.Postgrad Med,2005,118:35-46.
|
3. |
Schwartz DN,Furumoto-Dawson A,Itokazu GS,et al.Preventing mismanagement of community-acquired pneumonia at an urban public hospital:implications for institution-specific practice guidelines.Chest,1998,113(Suppl 3):194S-198S.
|
4. |
Mandell LA,Wunderink RG,Anzueto A,et al.Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.Clin Infect Dis,2007,44(Suppl 2):S27-S72.
|
5. |
American Thoracic Society;Infectious Diseases Society of America.Guidelines for the management of adults with hospital-acquired,ventilator-associated,and healthcare-associated pneumonia.Am J Respir Crit Care Med,2005,171:388-416.
|
6. |
Hospital-acquired pneumonia in adults:diagnosis,assessment of severity,initial antimicrobial therapy,and preventive strategies.A consensus statement,American Thoracic Society,November 1995.Am J Respir Crit Care Med,1996,153:1711-1725.
|
7. |
Woodhead M,Blasi F,Ewig S,et al.Guidelines for the management of adult lower respiratory tract infections.Eur Respir J,2005,26:1138-1180.
|
8. |
Owens RC Jr,Ambrose PG,Nightingale CH.Antibiotic Optimization.Concepts and Strategies in Clinical Practice.New York:Marced Dekker,2005,491-518.
|
9. |
El Moussaoui R,de Borgie CA,van den Broek P,et al.Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia:randomised,double blind study.BMJ,2006,332:1355.
|
10. |
D’Ignazio J,Camere MA,Lewis DE,et al.Novel,single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults.Antimicrob Agents Chemother,2005,49:4035-4041.
|
11. |
Tellier G,Niederman MS,Nusrat R,et al.Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia.J Antimicrob Chemother,2004,54:515-523.
|
12. |
Dunbar LM,Wunderink RG,Habib MP,et al.High-dose,short-course levofloxacin for community-acquired pneumonia:a new treatment paradigm.Clin Infect Dis,2003,37:752-760.
|
13. |
Dennesen PJ,van der Ven AJ,Kessels AG,et al.Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia.Am J Respir Crit Care Med,2001,163:1371-1375.
|
14. |
Chastre J,Wolff M,Fagon JY,et al.Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults:a randomized trial.JAMA,2003,290:2588-2598.
|
15. |
Parienti JJ,Ramakers M,Charbonneau P,et al.Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit.Am J Respir Crit Care Med,2001,164:172-173.
|
16. |
Zinner SH,Young LS,Acar JF,et al.Expanding indications for the new macrolides,azalides and streptogramins.New York:Marcel Dekker,1997,27-38.
|
17. |
Meehan TP,Fine MJ,Krumholz HM,et al.Quality of care,process,and outcomes in elderly patients with pneumonia.JAMA,1997,278:2080-2084.
|
18. |
Houck PM,Bratzler DW,Nsa W,et al.Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia.Arch Intern Med,2004,164:637-644.
|